永安药业(002365) - 2025 Q2 - 季度业绩预告

Core Performance Forecast Data The company anticipates a significant year-over-year decline in its 2025 first-half performance, with net profit attributable to shareholders projected to decrease by 71.39% to 80.91% Performance Forecast Summary | Item | Current Reporting Period (Jan 1 - Jun 30, 2025) | Prior Period | | :--- | :--- | :--- | | Net Profit Attributable to Shareholders of Listed Company | Profit: 10.0177 million yuan - 15.0177 million yuan | Profit: 52.4852 million yuan | | Year-over-Year Change | Decrease 80.91% to 71.39% | - | | Net Profit After Deducting Non-Recurring Gains and Losses | Profit: 1.8883 million yuan - 2.8083 million yuan | Profit: 35.9768 million yuan | | Year-over-Year Change | Decrease 94.75% to 92.19% | - | | Basic Earnings Per Share | Profit: 0.0346 yuan/share – 0.0519 yuan/share | Profit: 0.1781 yuan/share | Explanation of Performance Changes The company attributes the significant decline in first-half performance to a sluggish market, resulting in year-over-year decreases in taurine's production, sales volume, and selling price - The primary reason for the performance decline is the sluggish market, which led to year-over-year decreases in both production and sales volume, as well as the selling price, of the company's main product, taurine[5] Communication with Accounting Firm This performance forecast is unaudited, but preliminary discussions have been held with the annual report auditing accounting firm regarding the forecast - This performance forecast is unaudited, but preliminary discussions have been held with the annual report auditing accounting firm[4] Risk Warning The company states this performance forecast is a preliminary estimate, with final accurate financial data to be based on the officially disclosed 2025 semi-annual report, advising investors to be aware of related investment risks - This performance forecast is a preliminary estimate, and specific financial data will be based on the company's disclosed 2025 semi-annual report[6] - The company advises investors to be aware of investment risks[7]